TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31850484

Group type: EXPERIMENTAL
Intervention: Combined mouthwash formulation containing natural antibiofilm agents
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combined mouthwash formulation
Number of subjects: 30
Study: 31317942

Group type: EXPERIMENTAL
Intervention: Endoscopic partial papillosphincterotomy combined with balloon dilatation (main group A)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Endoscopic papillosphincterotomy (clinical comparison 1)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Endoscopic papillosphincterotomy with mechanical lithotripsy (clinical comparison 2)
Number of subjects: 90
Study: 28656510

Group type: EXPERIMENTAL
Intervention: Alprostadil hydration (10 μg/day for 3 days plus 20 ml normal saline)
Number of subjects: 451

Group type: COMPARATOR
Intervention: Control group (20 ml normal saline for 3 days)
Number of subjects: 451
Study: 24691565

Group type: EXPERIMENTAL
Intervention: Faith-oriented smoking cessation program
Number of subjects: 590

Group type: COMPARATOR
Intervention: Delayed intervention group
Number of subjects: 590
Study: 23321226

Group type: EXPERIMENTAL
Intervention: Foraminal enlargement instrumentation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard nonenlargement instrumentation (Control)
Number of subjects: 40
Study: 21730076

Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcium-channel blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 0
Study: 19501611

Group type: EXPERIMENTAL
Intervention: Equiluminant weaves
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Luminance-mismatched weaves
Number of subjects: 0
Study: 16876058

Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine
Number of subjects: 20

Group type: COMPARATOR
Intervention: 2% mepivacaine with 1:100,000 epinephrine
Number of subjects: 20
Study: 15316192

Group type: EXPERIMENTAL
Intervention: Whitening dentifrice
Number of subjects: 14

Group type: COMPARATOR
Intervention: Regular dentifrice
Number of subjects: 14
Study: 10776363

Group type: EXPERIMENTAL
Intervention: Depression Management Program (DMP)
Number of subjects: 407
Study: 9348365

Group type: EXPERIMENTAL
Intervention: Chlamydia trachomatis IgG titers positive
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Age analysis of positive Chlamydia trachomatis IgG titers
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Chlamydia pneumoniae titers positive
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Chlamydia trachomatis titers positive
Number of subjects: 51
Study: 8375999

Group type: EXPERIMENTAL
Intervention: Interslice compression algorithm at compression ratios of 5:1, 10:1, and 15:1
Number of subjects: 3

Group type: COMPARATOR
Intervention: Intraslice compression algorithm at compression ratios of 5:1, 10:1, and 15:1
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Interslice compression algorithm at 10:1
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Overall agreement among radiologists
Number of subjects: 3
Study: 3532009

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg three times a day for 4 weeks)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (identical to nifedipine, three times a day for 4 weeks)
Number of subjects: 22
Study: 29715355

Group type: EXPERIMENTAL
Intervention: Glyburide (n=460)
Number of subjects: 914

Group type: COMPARATOR
Intervention: Insulin (n=454)
Number of subjects: 914
Study: 28049818

Group type: COMPARATOR
Intervention: Short-chain galactooligosaccharide (GOS) treatment, designated 'RP-G28', administered over 36 days.
Number of subjects: 30
Study: 26022709

Group type: EXPERIMENTAL
Intervention: FLAM (flavopiridol 50 mg/m(2) days 1‐3, cytarabine 667 mg/m(2)/day continuous infusion days 6‐8, and mitoxantrone 40 mg/m(2) day 9)
Number of subjects: 165

Group type: COMPARATOR
Intervention: 7+3 (cytarabine 100 mg/m(2)/day continuous infusion days 1‐7 and daunorubicin 90 mg/m(2) days 1‐3)
Number of subjects: 165

Group type: COMPARATOR
Intervention: 7+3+/-5+2 (cytarabine 100 mg/m(2)/day continuous infusion days 1‐5 and daunorubicin 45 mg/m(2) days 1‐2)
Number of subjects: 165
Study: 23471041

Group type: EXPERIMENTAL
Intervention: Experimental group (ICED) - deceived of the actual cycling intensity
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (ICEC) - informed of the actual protocol
Number of subjects: 16
Study: 21497022

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (1.5 mg/kg followed by two boluses of 0.5 mg/kg at 5-min intervals and continuous infusion)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride administered at equivalent volume, dose and rate to lidocaine)
Number of subjects: 45
Study: 18227847

Group type: EXPERIMENTAL
Intervention: Dietary counseling (ten 1-hour consultations)
Number of subjects: 50
Study: 16421781

Group type: EXPERIMENTAL
Intervention: Outer upper arm vaccination
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Inner upper arm vaccination
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 20
Study: 12925034

Group type: EXPERIMENTAL
Intervention: Lepirudin (bolus 0.1 mg kg‐1, continuous infusion of 0.1 mg kg‐1 h‐1)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 24
Study: 12162483

Group type: EXPERIMENTAL
Intervention: HPMC-containing solution
Number of subjects: 35

Group type: COMPARATOR
Intervention: Multipurpose solutions without HPMC
Number of subjects: 35
Study: 9672932

Group type: EXPERIMENTAL
Intervention: Withholding oral fluids for 4-6 hours postoperatively
Number of subjects: 317

Group type: COMPARATOR
Intervention: Drinking oral fluids postoperatively
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Withholding oral fluids in patients receiving opioids
Number of subjects: 317
Study: 7916445

Group type: EXPERIMENTAL
Intervention: Atropine and chlordesmethyldiazepam (0.03 mg/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Atropine and diazepam (0.015 mg/kg)
Number of subjects: 40
Study: 2690395

Group type: EXPERIMENTAL
Intervention: 252Cf neutron component applied by means of intracavitary therapy at the beginning of the therapeutic cure
Number of subjects: 56

Group type: COMPARATOR
Intervention: Conventional 226Ra therapy (control group)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 252Cf neutron component
Number of subjects: 56
Study: 30981620

Group type: EXPERIMENTAL
Intervention: FSH
Number of subjects: 684

Group type: COMPARATOR
Intervention: Clomiphene citrate
Number of subjects: 684
Study: 28939164

Group type: EXPERIMENTAL
Intervention: Testosterone administration
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 90
Study: 25599450

Group type: EXPERIMENTAL
Intervention: Bottom-up modulation (stimulus intensity)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Top-down modulation (placebo analgesia)
Number of subjects: 0
Study: 22633681

Group type: EXPERIMENTAL
Intervention: Nonsmoking (as a prognostic factor)
Number of subjects: 660

Group type: COMPARATOR
Intervention: Poor recovery trend group (patterns 4-14)
Number of subjects: 660
Study: 21192304

Group type: EXPERIMENTAL
Intervention: Clonidine (200 or 400 mcg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Triamcinolone (40 mg)
Number of subjects: 26
Study: 19523011

Group type: EXPERIMENTAL
Intervention: 180 microg week(‐1) PEG‐IFN alpha‐2a (40KD) + ribavirin (1000/1200 mg day(‐1)) for 48 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 270 microg week(‐1) PEG‐IFN alpha‐2a (40KD) + ribavirin (1000/1200 mg day(‐1)) for 48 weeks
Number of subjects: 40
Study: 17577435

Group type: EXPERIMENTAL
Intervention: Specific treatment group (intravascular embolism followed by immediate CSF drainage)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Conventional expectant treatment group
Number of subjects: 84
Study: 14710138

Group type: EXPERIMENTAL
Intervention: Oronasopharyngeal bulb suctioning at birth
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no bulb suctioning)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 11432512

Group type: EXPERIMENTAL
Intervention: Excision
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Conservative treatment with 0.2% glyceryl trinitrate ointment
Number of subjects: 150
Study: 10052665

Group type: EXPERIMENTAL
Intervention: HLX (high-low exercise order) - starts with intense sprints followed by less intense sprints
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: LHX (low-high exercise order) - starts with less intense sprints followed by intense sprints
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: HLX
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: LHX
Number of subjects: 11
Study: 8205085

Group type: EXPERIMENTAL
Intervention: hyperimmune immunoglobulins
Number of subjects: 0

Group type: COMPARATOR
Intervention: no immunoglobulins (control)
Number of subjects: 0
Study: 30240771

Group type: EXPERIMENTAL
Intervention: Clips
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Monopolar cauterization
Number of subjects: 70
Study: 26346997

Group type: EXPERIMENTAL
Intervention: S- (stopcock disconnected)
Number of subjects: 60

Group type: COMPARATOR
Intervention: S+ (stopcock attached)
Number of subjects: 60
Study: 24632222

Group type: EXPERIMENTAL
Intervention: Asymptomatic AF
Number of subjects: 157

Group type: COMPARATOR
Intervention: Symptomatic AF
Number of subjects: 157
Study: 23068960

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 160

Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 160
Study: 20037779

Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel (FEC-P)
Number of subjects: 0

Group type: COMPARATOR
Intervention: FEC (control)
Number of subjects: 0
Study: 19065852

Group type: EXPERIMENTAL
Intervention: Aligned zigzag line patterns
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Steepness and density of angles in aligned-angle patterns
Number of subjects: 0
Study: 15726659

Group type: EXPERIMENTAL
Intervention: EVL plus nadolol
Number of subjects: 80

Group type: COMPARATOR
Intervention: EVL alone
Number of subjects: 80
Study: 12927007

Group type: EXPERIMENTAL
Intervention: Mirtazapine (15‐45 mg/day)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Fluoxetine (20‐40 mg/day)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 133

Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 133
Study: 10365573

Group type: EXPERIMENTAL
Intervention: 1 month of exercise
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Non-strenuous exercise
Number of subjects: 27
Study: 8777930

Group type: EXPERIMENTAL
Intervention: Exclusively breast milk for at least 4 weeks (n = 206)
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Breast milk plus extensively hydrolysed formula (n = 50)
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Extensively hydrolysed cow's milk formula for 2 months, followed by conventional cow's milk (n = 82)
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Breast milk plus initial conventional cow's milk formula (n = 73)
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Conventional cow's milk with or without breast milk throughout (n = 187)
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Breast milk plus initial partially hydrolysed formula (n = 104)
Number of subjects: 702
Study: 2053556

Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 6683566

Group type: COMPARATOR
Intervention: Argon laser photocoagulation
Number of subjects: 11

Group type: COMPARATOR
Intervention: Xenon arc photocoagulation
Number of subjects: 11
Study: 29734896

Group type: EXPERIMENTAL
Intervention: 5 mg triamcinolone acetonide
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: 10 mg triamcinolone acetonide
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: 20 mg triamcinolone acetonide
Number of subjects: 93
Study: 27448667

Group type: EXPERIMENTAL
Intervention: Bendiocarb
Number of subjects: 2704

Group type: COMPARATOR
Intervention: Deltamethrin
Number of subjects: 2704
Study: 24597289

Group type: EXPERIMENTAL
Intervention: Combined administration of GnRH agonist with recombinant hCG (rhCG)
Number of subjects: 120

Group type: COMPARATOR
Intervention: rhCG alone
Number of subjects: 120
Study: 22730390

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) - 4 × 5‐min 220‐mmHg bilateral occlusion
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sham intervention - 4 × 5‐min 20‐mmHg bilateral occlusion
Number of subjects: 13
Study: 20431040

Group type: EXPERIMENTAL
Intervention: Azathioprine and prednisolone
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Cyclosporine monotherapy
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Cyclosporine monotherapy followed by azathioprine and prednisolone after 3 months
Number of subjects: 489

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 489
Study: 18378552

Group type: EXPERIMENTAL
Intervention: Mecamylamine (MECA, 20 mg, oral)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Scopolamine (SCOP, 2.5 microg/kg, i.v.)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 16006574

Group type: EXPERIMENTAL
Intervention: Laparoscopic colorectal resection
Number of subjects: 818

Group type: COMPARATOR
Intervention: Open colorectal resection
Number of subjects: 818
Study: 12449254

Group type: EXPERIMENTAL
Intervention: Videotape instruction for home exercise program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Personal instruction by a physical therapist
Number of subjects: 0
Study: 10359889

Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol xinafoate 42 microgram twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral zafirlukast 20 mg twice daily
Number of subjects: 0
Study: 8984127

Group type: EXPERIMENTAL
Intervention: Postprandial SBP change in Parkinson's disease patients
Number of subjects: 20

Group type: COMPARATOR
Intervention: Postprandial SBP change in control patients
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Orthostatic SBP responses in Parkinson's disease patients
Number of subjects: 20

Group type: COMPARATOR
Intervention: Orthostatic SBP responses in control patients
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Orthostatic heart rate responses in Parkinson's disease patients
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Effect of meal on orthostatic blood pressure
Number of subjects: 20
Study: 1709240

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg b.i.d.)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Chlorthalidone (25 mg o.d.)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Combination of nifedipine and chlorthalidone (20 mg b.i.d. and 25 mg o.d.)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 6451257

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (500 micrograms by nebuliser)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide given two hours before or after nebulised salbutamol
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide in addition to salbutamol
Number of subjects: 28
Study: 31178377

Group type: EXPERIMENTAL
Intervention: ROTAVAC® (3 doses)
Number of subjects: 464

Group type: COMPARATOR
Intervention: Rotarix® (2 doses)
Number of subjects: 464
Study: 28631502

Group type: EXPERIMENTAL
Intervention: Patent infarct-related artery (TIMI flow 2/3)
Number of subjects: 1863
Study: 27177231

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: COMPARATOR
Intervention: CHO-only
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CHO-casein
Number of subjects: 8

Group type: COMPARATOR
Intervention: CHO-whey
Number of subjects: 8
Study: 25052936

Group type: EXPERIMENTAL
Intervention: Synchronous distance-education technology (online delivery)
Number of subjects: 1711

Group type: COMPARATOR
Intervention: In-person delivery (control)
Number of subjects: 1711
Study: 23106838

Group type: EXPERIMENTAL
Intervention: Fissure sealant with oral hygiene instructions
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral hygiene instructions only (Control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fissure sealant
Number of subjects: 60
Study: 19918250

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MD)
Number of subjects: 776

Group type: COMPARATOR
Intervention: Control group (conventional low‐fat diet)
Number of subjects: 776
Study: 17764475

Group type: EXPERIMENTAL
Intervention: 30 min exercise starting immediately after dosing (EX0)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 30 min exercise starting 30 min after dosing (EX30)
Number of subjects: 12

Group type: COMPARATOR
Intervention: No exercise (NOEX)
Number of subjects: 12
Study: 15926116

Group type: EXPERIMENTAL
Intervention: Insulin glulisine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Regular human insulin (RHI)
Number of subjects: 16
Study: 12691686

Group type: EXPERIMENTAL
Intervention: Pain hot line
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Weekly provider-initiated follow-up calls for 1 month post-education
Number of subjects: 64

Group type: COMPARATOR
Intervention: Baseline pain education program
Number of subjects: 64

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 64
Study: 11115255

Group type: EXPERIMENTAL
Intervention: Psychological stress
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Systemic infection
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Other exposure variables (sunlight exposure, menstrual period, contact lens wear, eye injury)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Retrospective reporting of high stress
Number of subjects: 308
Study: 8932953

Group type: EXPERIMENTAL
Intervention: Thymostimulin (TP1) for 10 days pre- and 6 months post-operatively
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (non-TP1 treated patients)
Number of subjects: 61
Study: 1447385

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine (CHX)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sterile water
Number of subjects: 60
Study: 3797487

Group type: EXPERIMENTAL
Intervention: Crystalline salt added to food for 4 weeks
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Salt tablets for 4 weeks
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Crystalline salt added to food for 6 weeks
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Salt tablets for 6 weeks
Number of subjects: 3
Study: 30874781

Group type: EXPERIMENTAL
Intervention: Immediate Intervention (II) group
Number of subjects: 324

Group type: COMPARATOR
Intervention: Delayed Intervention (DI) group
Number of subjects: 324
Study: 29378536

Group type: EXPERIMENTAL
Intervention: HeadCoach online training intervention for managers
Number of subjects: 168

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 168
Study: 27247178

Group type: EXPERIMENTAL
Intervention: Youths (ages 18 to 24)
Number of subjects: 164
Study: 21989635

Group type: EXPERIMENTAL
Intervention: Repetitive task specific training (RTP) for 6 weeks, approximately 2.5 hours per day, split into two sessions, with epidural cortical stimulation co-administered
Number of subjects: 5
Study: 22835600

Group type: EXPERIMENTAL
Intervention: Omega-3 polyunsaturated fatty acids (PUFAs) administered at ≥2.7 g/day for a minimum duration of 3 months
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Omega-3 polyunsaturated fatty acids (PUFAs)
Number of subjects: 370

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 370
Study: 21047588

Group type: EXPERIMENTAL
Intervention: High grade PIN
Number of subjects: 56653

Group type: EXPERIMENTAL
Intervention: LSPC
Number of subjects: 56653

Group type: COMPARATOR
Intervention: Screening rounds 1, 2, and 3
Number of subjects: 56653
Study: 17607078

Group type: EXPERIMENTAL
Intervention: Nutritional agents such as active vitamin D3 and vitamin K2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-resorbers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin D
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extra-skeletal mechanisms of vitamin D
Number of subjects: 0
Study: 15687102

Group type: EXPERIMENTAL
Intervention: Social-cognitive intervention with stage-targeted letters and interpersonal counseling
Number of subjects: 651

Group type: EXPERIMENTAL
Intervention: Social-cognitive intervention
Number of subjects: 651

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 651
Study: 12006898

Group type: EXPERIMENTAL
Intervention: Moclobemide (75, 150, 300, 600, or 900 mg/day)
Number of subjects: 452

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 452
Study: 10096263

Group type: EXPERIMENTAL
Intervention: Interleukin-10 (8 microg/kg subcutaneous injection)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Prednisolone (15 mg by mouth)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo with prednisone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Joint effects of interleukin-10 and prednisolone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Interleukin-10
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dynamic modeling
Number of subjects: 12
Study: 8641320

Group type: EXPERIMENTAL
Intervention: Idrapril calcium (200 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 2156913

Group type: EXPERIMENTAL
Intervention: Pulsed Doppler ultrasound
Number of subjects: 8

Group type: COMPARATOR
Intervention: Continuous wave Doppler ultrasonography
Number of subjects: 8
Study: 6928104

Group type: EXPERIMENTAL
Intervention: Central nervous system prophylaxis (CNS‐P)
Number of subjects: 99

Group type: COMPARATOR
Intervention: No prophylaxis (Control)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Induction regimen (vincristine plus low-dose methotrexate and high-dose prednisone)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: CNS‐P
Number of subjects: 99
Study: 31714037

Group type: EXPERIMENTAL
Intervention: Personalized decision support intervention
Number of subjects: 57
Study: 31138676

Group type: EXPERIMENTAL
Intervention: 7-week online mindfulness-based intervention (MBI)
Number of subjects: 323

Group type: COMPARATOR
Intervention: Control group (wait list)
Number of subjects: 323
Study: 27967288

Group type: EXPERIMENTAL
Intervention: Kabat physical rehabilitation combined with steroid treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Steroid treatment alone
Number of subjects: 100